Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The ESMO Targeted Anticancer Therapies Congress 2021, designed for basic scientists, physicians and translational researchers belonging to academic settings, industry and regulatory agencies will be held as a virtual meeting.
Researchers Predict Over 1.4 Million Deaths From Top 10 Cancers in 2021 in the EU and UK. Accompanying Editorial Warns of Adverse Effect of COVID-19 on Death Rates.
A study of 44,541 women has found that there appears to be no association between type 2 diabetes and developing breast cancer overall.
The global coronavirus pandemic has disrupted cancer research, prevention and treatment to an extent never seen before.
The ESMO Immuno-Oncology Congress 2020, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as a virtual meeting.
The ESMO Asia Congress 2020, the leading scientific platform in the Asia-Pacific region, will be held as a virtual meeting.
The Molecular Analysis for Precision oncology (MAP) Congress is designed to answer the critical question about how to integrate the wealth of information coming from the analysis of tumour samples into daily practice.
New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and oesophageal cancers who currently have poor survival.
Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.
Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant chemotherapy shows no statistically significant difference in 3-year disease-free survival (DFS), according to data presented at ESMO 2020.
The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
